About

About Alnylam Alnylam has led the translation of RNA interference into a new class of approved and investigational medicines for transthyretin amyloidosis (TTR), rare, cardiovascular, metabolic, neurologic and other diseases. Learn more: www.alnylam.com. Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information, please visit www.alnylam.com.